Direct Immunofluorescence using flow cytometric techniques.
Evaluation of Rituximab therapy. A full lymphoid cell panel is run, including B and T cell quantitation and natural killer cell quantitation. Markers include CD3, CD4, CD8, CD16/56, CD19, CD20 and CD4:CD8 ratio (T4:T8 ratio). See http://www.pathology.med.umich.edu/handbook/Tables/Flow_Cytometry_Panel… for all Flow Cytometry Panels.
RITUXAN reference range.docx
*Pediatric Reference Ranges from Journal of Allergy and Clinical Immunology, vol. 112, No. 5, 11/2003 and studies performed at Michigan Medicine Flow Cytometry Laboratory. Absolute ranges are calculated utilizing absolute lymphocyte count ranges for the same age groups provided by the hematology laboratory.
Requires viable cells which have been stored at room temperature (18-22 degrees C) for
Saturday: 7:00am - 3:00pm
24 - 48 hours
- Generic Flow Test
- Markers CD3 CD4 CD8 CD16/56 CD19 CD20
- Rituxan Therapy
- Rituximab Treatment Profile
- Lymphoma Treatment
- RITUXIMAB PANEL
- Panel 7: Rituximab
- Rituxan Panel Shadow
Collect specimen in a yellow top ACD A or B Vacutainer® tube.
Include a copy of the patient's complete blood count (CBC) and white cell differential drawn concurrently or within the previous 8 hours.
Send intact whole blood stored at room temperature within 72 hours of collection; do not refrigerate.
Additional testing will be run at the discretion of the hematopathologist at an additional charge with interpretation if clinically indicated. By ordering this test the clinician acknowledges that additional reflex testing will be performed and billed at a separate additional charge if indicated. For consultation, contact the MLabs Client Services Center or Flow Cytometry Laboratory at 76-39420.